C4 Therapeutics, Inc. (CCCC)

US — Healthcare Sector
Peers: STTK  ELYM  PRLD  GLUE  FHTX  CYT  RZLT  IPSC  EWTX  MLYS  CGEM  ARVN  NRIX  KYMR  RVMD 

Automate Your Wheel Strategy on CCCC

With Tiblio's Option Bot, you can configure your own wheel strategy including CCCC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CCCC
  • Rev/Share 0.5616
  • Book/Share 2.7549
  • PB 0.5336
  • Debt/Equity 0.3298
  • CurrentRatio 5.6966
  • ROIC -0.3937

 

  • MktCap 104380437.0
  • FreeCF/Share -1.1365
  • PFCF -1.2966
  • PE -1.0082
  • Debt/Assets 0.2014
  • DivYield 0
  • ROE -0.4586

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade CCCC Wells Fargo Equal Weight Overweight $8 $12 Dec. 19, 2024

News

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates
CCCC
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.41 per share a year ago.

Read More
image for news C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
CCCC
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral

Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µ g, Including One Patient With a Minimal Residual Disease Negative Complete Response ; 40% ORR Achieved at the 75 µ g Dose Level

Read More
image for news C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
CCCC
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026

Read More
image for news C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
C4 Therapeutics to Participate in Upcoming March Investor Conferences
CCCC
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in two upcoming March investor conferences.

Read More
image for news C4 Therapeutics to Participate in Upcoming March Investor Conferences

About C4 Therapeutics, Inc. (CCCC)

  • IPO Date 2020-10-02
  • Website https://www.c4therapeutics.com
  • Industry Biotechnology
  • CEO Mr. Andrew J. Hirsch M.B.A.
  • Employees 110

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.